The elfects of pre-and postprandial levels of lipids in serum on the experimental in vivo and in vitro toxicities of amphotericin B deoxycholate (AmB-d) were studied. Normal OF1 mice were tested at baseline, after normal feeding, after 3 h of fasting, or after a sequence of feeding and fasting and vice versa. The 50%o lethal dose (LD50) of AmB-d was significantly higher in fed mice than in mice which fasted or at baseline (2.38 + 0.12 versus 1.53 ± 0.2 and 1.50 ± 0.1 mg/kg of body weight, respectively; P < 0.05). When different nutritional regimens were alternated over a short period, the level of in vivo AmB-d toxicity was dictated by the last feeding regimen. Serum triglycerides, but not cholesterol in very-low-density and low-density lipoproteins, correlated significantly (P < 0.01) with the LD50 of AmnB. In vitro experiments showed that the addition of human serum reduced AmB-d-induced toxicity against human erythrocytes, but serum drawn after fasting was less protective than postprandial serum. However, neither serum decreased the in vitro activity of AmB-d against Candida albicans. Circular dichroism, a method that enables the amount of free AmB to be measured, showed that, both mouse and human total serum lipoproteins bound more AmB-d when serum was isolated postprandially than when it was obtained after fasting. Our results show that AmB-d toxicity is reduced by feeding-induced modifications in serum lipids. The influence of food intake on the clinical toxicity of the drug merits being investigated.
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Parenteral amphotericin B (AmB) is the reference treatment for many systemic mycoses. However, its therapeutic use is hampered by a high level of side effects (13, 25) . Therefore, many strategies have been developed in an attempt to reduce the toxicity of the commercial formulation for the intravenous route, AmB deoxycholate (AmB-d [Fungizone] ). AmB is lipophilic, and its association with liposomes, lipid emulsions, or surfactant leads to a reduction of its toxicity without altering its antifungal activity (2, 3, 7, 14, 16) . Some of these formulations are now available for clinical use. They have significant antifungal activity but continue to exhibit some residual toxicity (12, 18) and are very expensive. Since AmB binds to lipoproteins in human serum (5) , we hypothesized that the endogenous lipids included in circulating lipoproteins could interfere with AmB-d toxicity. The lipid content of human serum is acutely altered by eating, fasting, or stress (11) , and the influences of such variations on AmB-induced toxicity could be significant clinically.
This study was designed to investigate the effects of fasting and feeding on in vivo AmB-d-induced toxicity in mice and to study the In vivo toxicity. Fifty-percent lethal doses (LD50s) and confidence intervals were determined as previously described (22, 23 RESULTS Influence of food intake on in vivo AmB-d-induced toxicity and on lipid content in serum in mice. The AmB-d LD50 was significantly higher (P < 0.05) in fed mice (2.38 ± 0.12 mg/kg of body weight) than in fasted mice (1.53 ± 0.2 mg/kg) or at baseline (1.50 ± 0.1 mg/kg) (Fig. 1) . Triglyceride levels were also significantly higher (P < 0.05) in fed than in fasted mice or at baseline. The mean VLDL-LDL cholesterol level in fed mice was similar to the value measured at baseline but was higher than that observed in fasted mice (P < 0.05) ( Table   1) .
To further document the effect of diet on the in vivo AmB-d-induced toxicity, two additional experiments were performed: in one, mice were fasted for 3 h and then were fed for 3 h before the LD50 was measured; in the other, mice were fed and then fasted before the LD50 was measured. The level of AmB-d toxicity was dictated by the last feeding regimen: mice that were fed and then fasted for 3 h before AmB-d administration had low LD50s (1.6 ± 0.2 mg/kg). Conversely, 3 h of food uptake after fasting promptly increased the AmB-d LD50 (P < 0.05).
A wide range of LD50s was obtained with the five feeding 3A) and against K+ release induced by 5 ,uM AmB-d (P < 0.05) (Fig. 3B) .
However, human serum drawn either before or after eating had no influence on the AmB-d-induced K+ release by and viability of C. albicans ( Fig. 3C and D 
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and on lipid content in serum in mice. The AmB-d LD50 was significantly higher (P < 0.05) in fed mice (2.38 ± 0.12 mg/kg of body weight) than in fasted mice (1.53 ± 0.2 mg/kg) or at baseline (1.50 ± 0.1 mg/kg) (Fig. 1) . Triglyceride levels were also significantly higher (P < 0.05) in fed than in fasted mice or at baseline. The mean VLDL-LDL cholesterol level in fed mice was similar to the value measured at baseline but was higher than that observed in fasted mice (P < 0.05) ( Table  1) .
A wide range of LD50s was obtained with the five feeding regimens. We studied the correlation between LD50 and lipid levels, using the LD50 and the mean triglyceride or VLDL-LDL cholesterol value obtained from the same experiment. Triglycerides (in millimoles per liter) correlated with AmB LD50s (milligrams per kilogram) (linear regression: y = 0.91 x + 0.108; R = 0.71; P = 0.0066) (Fig. 2A) . There was no significant correlation between VLDL-LDL cholesterol and the AmB LD50 (P = 0.25) (Fig. 2B) .
Influence of serum from fasted or fed volunteers on the in vitro toxicity and activity of AmB-d. In order to investigate whether the above results might be extended to AmB toxicity in patients, the protective role of human pre-or postprandial serum against in vitro AmB toxicity was measured. Normal human serum was obtained either after 12 to 14 h of fasting (preprandial serum) or 4 h after a meal (postprandial serum), and human RBCs were exposed to AmB-d in the absence or presence of serum. AmB-d was less toxic against human RBCs in the presence of serum, but postprandial serum was more protective than preprandial serum against RBC hemolysis induced by 25 ,uM AmB-d (P < 0.05) (Fig. 3A) and against K+ release induced by 5 ,uM AmB-d (P < 0.05) (Fig. 3B) . However, human serum drawn either before or after eating had no influence on the AmB-d-induced K+ release by and viability of C. albicans (Fig. 3C and D) . Comparison of lipid concentrations before and after eating showed that total cholesterol levels did not differ, whereas eating increased 
DISCUSSION
Our results demonstrated mainly that the acute in vivo toxicity of AmB in normal mice was closely related to the feeding pattern. The consequences of food intake on AmB toxicity were rapid and reversible, as shown by the predominant influence of the most recent feeding regimen over a short period of time (less than 3 h).
By means of in vivo and in vitro experiments, we investigated whether these modifications in AmB toxicity were associated with alterations in serum lipids resulting from the different diets imposed. Few in vivo investigations have been performed in this field, and contradictory results have been reported. Koldin et al. (19) failed to demonstrate both the protective effect of high serum cholesterol levels against AmB toxicity in rabbits and the reduced in vivo toxicity of AmB complexed in vitro to lipoproteins. By contrast, Wasan et al. (27) showed that experimentally diabetic rats exhibited an increased tolerance to AmB and a marked increase in serum cholesterol and triglyceride levels. In both studies, serum lipid values were abnormal, due to diabetes or administration of a special diet, leading to experimental conditions that were far from the physiologic situation. To correlate the in vivo toxicity of AmB with changes in the serum lipoprotein content, we chose the mouse model for the following reasons. First, acute lethality after intravenous AmB administration is a simple and reproducible way to investigate AmB toxicity, although the mechanism of death is not known. Second, mouse lipoproteins are well described and easy to isolate from serum (9, 10) . We chose to study the consequences on AmB toxicity of spontaneous lipid variations in normal animals, since these variations over a 24-h period, with a normal nutrition and after fasting, paralleled the variations in lipids seen in human serum after a meal or after fasting. The decrease in VLDL-LDL cholesterol during fasting was expected in mice, since, unlike other animal species, mice lack cholesteryl ester transfer activity (15) , responsible for transferring cholesteryl ester from HDL back to LDL. We selected a relatively short (3-h) fasting duration in order to avoid the influence of weight loss on our results.
Our data suggest that modifications in serum lipids related to normal feeding were associated with a decrease in AmB toxicity. LD50s correlated with serum triglyceride values but not with VLDL-LDL cholesterol values. This association between an increase in triglycerides and a reduction in AmB-d toxicity suggested that the triglycerides, or their main vehicle in serum, i.e., chylomicrons, LDL, and VLDL, were involved in the protective effect of feeding against AmB-d toxicity. Recently, Souza et al. (24) showed that a triglyceride-rich emulsion that behaves in vivo as chylomicrons was able to reduce the in vitro and in vivo toxicity of AmB. However, we cannot exclude that the protective effect of feeding was related to other, unexplored mechanisms, independent from triglycerides; triglyceride modifications would then be associated with diet alteration but not causally related to AmB-d toxicity.
The spectroscopic investigations shed some light on the possible mechanisms of protection afforded by serum lipid alterations. Free (protein-unbound) AmB is present in aqueous medium in three distinct physical states: soluble monomers, soluble oligomers, and insoluble aggregates. The concentration of the soluble oligomeric form of free AmB, thought to be the most toxic form (2, 4, 20) , was reduced in the presence of lipoproteins and was lower when the lipoproteins were isolated from post-rather than preprandial serum. The changes in AmB binding to isolated fractions with a density below 1.063, either from mice or from humans, were similar to those obtained with total lipoproteins, suggesting that diet influences, at least in part, the amount of free toxic drug by modifying its interactions with the VLDL-LDL fraction in mice or the VLDL-LDL fraction and chylomicrons in humans. Since this low-density fraction represents the triglyceride-rich lipoproteins, our binding experiments agree with the correlation between triglycerides and LD50 observed in vivo. VLDL and LDL have previously been reported to be more efficient than HDL in reducing the amount of free AmB (5) , and this was attributed to the higher cholesterol-to-phospholipid ratio in VLDL or LDL than in HDL. However, it has been shown recently that more than 50% of AmB was recovered in the HDL fraction (26) . We cannot exclude that AmB binding to HDL cholesterol was affected by eating or fasting, but, since HDL cholesterol remained unchanged in mouse and human sera in our experiments, we did not investigate this point.
We also indirectly evaluated the protective effect of eating against AmB toxicity in humans by ex vivo experiments using RBCs. Although anemia under AmB therapy results from bone marrow suppression, more than from hemolysis, the interaction of polyene with RBCs has been widely studied since these cells are readily available and their membrane properties are well known. Serum sampled after the volunteers had eaten was more protective than serum drawn after fasting, in agreement with the reduction of free AmB soluble oligomers observed spectroscopically. The K+ release reflected alterations in membrane permeability, the first step of AmB cellular toxicity. We also investigated AmB-induced hemolysis and demonstrated that protection was not limited to changes of membrane permeability. The high concentrations of AmB tested against RBCs were not representative of the therapeutic concentrations but were selected because lower values were not toxic against RBCs under our experimental conditions because of the short incubation time. Our in vitro results confirmed in vivo data obtained for mice and suggest that they might bear some clinical relevance. Interestingly, antifungal activity remained stable in the presence of serum, drawn either pre-or postprandially. This retained antifungal activity agrees with previous reported data (5, 6, 24) and confirms the fact that the threshold of free AmB needed for interaction with yeast ergosterol-containing membranes is lower than that needed for interaction with cholesterol-containing mammalian cell membranes. This difference supports the selectivity of AmB against yeasts (4) .
The in vivo experiments were performed after a single administration of AmB. It has been suggested that AmB binding to lipoproteins may lead to increased internalization of the drug in cells bearing lipoprotein receptors (21) and thereby enhance the intracellular toxicity of the drug in the case of repeated administrations. It therefore remains to be investigated whether an increased binding of AmB to lipoproteins observed under conditions of chronic administration and normal feeding would have long-term deleterious effects.
